On July 2, CSPC Pharmaceutical rose 6.74% in regular trading, trading at 7.51 HKD/share, with turnover of 64.78 million HKD. The rally was driven by broad-based strength across the pharmaceutical sector combined with multiple company-specific catalysts continuing to ferment.

On the sector front, the pharmaceutical industry saw widespread gains, with Hengrui Pharma up 4.67%, Asymchem up 6.07%, and Fosun Pharma up 3.90%, providing strong sector-level support. On the company front, CSPC recently announced its core ADC drug SYS6010 combined with enlonstobart officially commenced a Phase III clinical trial in China for non-small cell lung cancer, with the first patient enrollment planned for July. Earlier Phase I/II data showed an objective response rate of 41.8% across 533 evaluable patients. Additionally, the semaglutide long-acting monthly injection received FDA clinical trial approval, and subsidiary CSPC Innovation re-filed its listing application with the Hong Kong Stock Exchange, providing multiple layers of positive catalysts.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)